Symptoms of Diabetes and Their Association With the Risk and Presence of Diabetes

Findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD)

  1. Nathaniel G. Clark, MD1,
  2. Kathleen M. Fox, PHD2,
  3. Susan Grandy, PHD3 and
  4. for the SHIELD Study Group *
  1. 1American Diabetes Association, Alexandria, Virginia
  2. 2Strategic Healthcare Solutions, Monkton, Maryland
  3. 3AstraZeneca, Wilmington, Delaware
  1. Address correspondence and reprint requests to Susan Grandy, PhD, AstraZeneca, 1800 Concord Pike, Wilmington, DE 19803. E-mail: susan.grandy{at}astrazeneca.com

Abstract

OBJECTIVE—The American Diabetes Association (ADA) lists seven symptoms of diabetes; however, it is not known how specific these symptoms are for initial diagnosis of type 2 diabetes. The Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) examined prevalence of ADA symptoms and their association with diabetes diagnosis.

RESEARCH DESIGN AND METHODS—SHIELD is a 5-year observational study of individuals with or at risk for diabetes diagnosis. Following an initial screening phase, follow-up questionnaires were mailed to a stratified random sample of individuals (n = 22,001) with type 1 or type 2 diabetes or at high (three to five risk factors) or low (zero to two risk factors) risk for diabetes. Individuals reported whether they experienced each ADA symptom, as well as symptoms unrelated to diabetes.

RESULTS—A total of 15,794 questionnaires were returned (response rate 71.8%). All ADA symptoms were reported more frequently in type 2 diabetes than in low- and high-risk groups (P < 0.0001 for each). Multivariable logistic regression analyses found that each ADA symptom other than irritability was significantly associated with type 2 diabetes, as was erectile/sexual dysfunction. However, 48% of type 1 diabetic and 44% of type 2 diabetic respondents reported no ADA symptom in the previous year.

CONCLUSIONS—Occurrence of ADA symptoms alone may not adequately identify those who should be evaluated for type 2 diabetes. Longitudinal data from SHIELD will evaluate whether combinations of symptoms or addition of other symptoms can better identify individuals for evaluation.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 21 August 2007. DOI: 10.2337/dc07-0816.

  • N.G.C. is currently affiliated with Novo Nordisk, Princeton, New Jersey.

  • *

    * A complete listing of the SHIELD Study Group members can be found in the appendix.

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted August 13, 2007.
    • Received April 26, 2007.
« Previous | Next Article »Table of Contents